← All institutions

Goldman Sachs

365 reports

Reports from this institution

Goldman Sachs

Goldman Sachs: GenFleet’s GFH276 debuts: Pancreatic cancer response rate exceeds Goldman Sachs’ expectations; subsequent dose selection is key

GFH276 achieved an objective response rate of 41% in pancreatic cancer patients treated predominantly in the third-line setting or later, exceeding Goldman Sachs’ previously established threshold. Efficacy and tolerability support further exploration, but higher doses showed no clear efficacy benefit, and skin toxicity and long-term tolerability will influence subsequent dose selection.

Goldman Sachs

Goldman Sachs: Telecom sector September tracker: 5G construction rebounds month on month, while optical cable exports outperform overall production

China added 59 thousand 5G base stations in September, but Goldman Sachs still expects full-year additions to be lower than in 2025. Optical cable export volume rose 52% year on year, diverging from a 22% decline in domestic output; base station exports continued to contract, with the improvement in overseas demand concentrated in certain segments.

Goldman Sachs

Goldman Sachs: Novartis’s remibrutinib falls short of investor efficacy thresholds: How much sales can its safety advantage support?

Goldman Sachs believes remibrutinib’s multiple sclerosis data fell short of investor expectations and that its better liver safety is insufficient to drive rapid replacement of existing therapies. The company has set a peak sales target of more than 8 billion US dollars across all indications, but evidence on switching treatments and the pace of physician adoption remain key constraints.

Goldman Sachs

Goldman Sachs: China’s property downturn is deeper, so why will its drag on the economy still gradually ease?

Goldman Sachs has raised its estimate of the direct drag from real estate on real GDP growth in 2026 from 1.5 percentage points to 1.8 percentage points, but expects it to narrow to 1.3 percentage points in 2027. The key is the property sector’s declining share of the economy; diverging home prices, shrinking household wealth and lost local land revenues will determine how long the adjustment lasts.

Goldman Sachs

Goldman Sachs: Cutting its South Korean stock market target to 9000 points. Why does it still see upside of more than sixty percent?

The KOSPI has fallen 40% from its June peak. Goldman Sachs believes memory stocks have priced in excessively pessimistic earnings assumptions, while non-memory stocks have also been caught in the sell-off. But sustained high volatility and slowing earnings revisions will continue to depress valuations, so it has cut its target from 12000 to 9000 points.

Goldman Sachs

Goldman Sachs: Goldman Sachs on Taiwan’s PCB supply chain: Customer-funded expansion, materials upgrades and ABF open up profit opportunities

Customers are beginning to support capacity for 2027–2030 through long-term contracts, advance payments or subsidies, prompting Goldman Sachs to raise its earnings outlook for the supply chain. Another growth avenue comes from upgrades to M10 materials and high-margin ABF substrate materials, but certification, yields and expansion progress will determine how quickly the opportunity materializes.

Goldman Sachs

Goldman Sachs: Range Intelligent Computing Technology: Third-quarter results below Goldman Sachs expectations as AI computing capacity expansion enters peak investment phase

Goldman Sachs attributes the third-quarter shortfall mainly to the timing gap between investment in computing capacity and revenue recognition, and expects contributions to increase from the fourth quarter. The bigger change is the company's plan to invest up to approximately 57 billion yuan in AI computing capacity from the fourth quarter of 2026 to the first quarter of 2027. The financing structure, payback period and utilization rate will determine the return on expansion.

Goldman Sachs

Goldman Sachs: InnoCare Pharma: A peer drug’s relapse control falls short of expectations. Why does this reinforce orelabrutinib’s progressive multiple sclerosis strategy?

Remibrutinib’s phase III trials delivered relapse control below the investor threshold cited by Goldman Sachs, but showed a favorable safety profile and signals of delayed disability progression. Goldman Sachs consequently sees greater merit in orelabrutinib’s strategy of focusing on progressive multiple sclerosis; the key to differentiation lies in its own phase III trials’ benefit in delaying disability progression.

Goldman Sachs

Goldman Sachs: Kelun-Biotech phase III lung cancer data: More durable efficacy strengthens case for replacing chemotherapy in first-line treatment

In Lung06, sac-TMT plus pembrolizumab achieved median progression-free survival of 15 months, above Goldman Sachs’ expectation of 9–12 months, with fewer serious adverse events than the chemotherapy combination. Goldman Sachs believes the data reduce global development risk, although follow-up duration and the applicability of Chinese data to global populations remain key conditions.

Goldman Sachs

Goldman Sachs: Goldman cuts Korean equity target but still sees sixty percent upside; Asian allocations shift toward cash flow and earnings delivery

Asian technology stocks have been sold off, but the regional earnings consensus for 2027 is still being revised upward. Goldman Sachs cut its KOSPI target from 12,000 to 9,000 points, while arguing that Korean valuations already price in excessively deep earnings downgrades. Its allocation approach places greater emphasis on value, financial quality and cash returns.

Goldman Sachs

Goldman Sachs: Cambricon’s third-quarter revenue missed Goldman Sachs’ forecast. Why is its long-term growth outlook unchanged?

Third-quarter revenue doubled year over year and gross margin continued to improve, but tight supply and the timing of purchases by major customers left revenue well below Goldman Sachs’ forecast. Goldman cut its 2026 earnings forecast, largely retained its medium-term growth outlook, and lowered its target price following a decline in industry valuations.